Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review. Hotspots ranked Start the day smarter ☀️ Funniest cap ...

Earnings Call Insights: Biogen Inc. (BIIB) Q1 2025 Management View CEO Chris Viehbacher highlighted Biogen's evolving portfolio, with newer products such as LEQEMBI, SKYCLARYS, and ZURZUVAE now ...

Leqembi, which Biogen shares with Eisai, became the second drug proven to slow the progression of Alzheimer's to win approval in the U.S. last summer.

Health Biogen’s Alzheimer’s drug Leqembi has full FDA approval now. Here’s what that means. "This confirmatory study verified that it is a safe and effective treatment for patients with ...

Biogen is pricing Leqembi at $26,500 per year, and Medicare coverage is necessary for a drug that expensive to generate significant revenue and be available to a wide group of patients.

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

In Q1, Biogen’s sales dropped 7% to $2.3 billion, with Alzheimer’s med Leqembi and Friedreich’s ataxia (FA) drug Skyclarys generating roughly $19 million and $78 million over that same ...

Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is now planning to grow its U.S. field force by 30% as it works with Eisai on direct to ...

Biogen's opportunity. Assuming Leqembi does ultimately secure Medicare reimbursement, Biogen will have a huge opportunity. Eisai priced the drug at a price of $26,500 per year.

Biogen continues to trade at a significant discount to mid-sized pharmaceuticals despite a solid drug pipeline and its long-term potential from LEQEMBI. ipopba/iStock via Getty Images ...

Biogen is officially pivoting away from Aduhelm, the first Alzheimer's treatment the Cambridge drugmaker made. ... Leqembi is the second Alzheimer's drug out of Biogen’s collaboration with Eisai.

Uptake of Biogen’s breakthrough Alzheimer’s drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter.